UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 29, 2011
Biogen Idec Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
|
Delaware
(State or other jurisdiction
of incorporation)
|
|
0-19311
(Commission
file number)
|
|
33-0112644
(IRS Employer
Identification No.) |
| |
|
|
|
133 Boston Post Road, Weston, Massachusetts
(Address of principal executive offices)
|
|
02493
(Zip Code) |
Registrant’s telephone number, including area code: (781) 464-2000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 8.01 Other Events
Biogen Idec Inc. has received antitrust clearance from
the U.S. Government under the Hart-Scott-Rodino Act for its previously announced collaboration with Portola
Pharmaceuticals, Inc. to develop and commercialize novel oral Syk inhibitors for the treatment of various
autoimmune and inflammatory diseases. Biogen Idec’s agreement with Portola is now effective and Biogen Idec will
pay Portola $36 million in cash and will purchase $9 million of Portola equity before the end of the year. Under
the terms of its collaboration and license agreement, Biogen Idec may also make additional payments of up to $508.5 million
based on the achievement of certain development and regulatory milestones. Biogen Idec will lead the global
development and commercialization efforts for the Syk inhibitor program in major indications such as rheumatoid
arthritis and lupus, while Portola will lead worldwide development and U.S. commercialization efforts for select smaller
indications as well as discovery efforts for follow-on Syk inhibitors. Portola retains an option to co-promote
alongside Biogen Idec in the United States in major indications. Worldwide costs and profits will be split by Biogen
Idec and Portola 75 percent and 25 percent, respectively.